Aerolase
Elevating the Standard of Care in Laser Skin Health

The desire to be attractive is universal and timeless. Utilizing medical treatments and procedures to enhance and beautify one’s physical appearance has always been popular. The past few decades have witnessed an upsurge in demand for laser treatments, which has brought aesthetic lasers to the center stage. The aesthetics laser market is driven by increasing demand for non-invasive aesthetic procedures, growing technological advancements, changing lifestyles, and growing disposable income even in less developed countries. As such, it is forecast to expand from 798.4 $ million in 2018 to 1.93 $ billion by 2026, at a CAGR of 10.8 percent. Various technology advancements have enabled pain-free procedures, boosting the rate of laser treatment adoption significantly. In addition, the new regulations imposed on cosmetic laser products have helped ensure their efficiency while treating the skin without adversely affecting it. The radiation safety performance standards defined by the Federal Regulations and the norms set by the Federal Food, Drug, and Cosmetic Act (FDCA) have all played a crucial role in the increasing utilization of energy-based devices within the dermatology space.

Despite these advancements, laser and other devices have not fully satisfied the growing patient demands for effective and safe improvement to prevalent skin issues like acne, rosacea, psoriasis, aged skin, hyper pigmentation, nail fungus as well as body issues such as fat reduction. Fast and affordable treatments have also been a challenge.

Accordingly, there exists a vast unmet need for a single, miniaturized, and easy-to-use dermatology laser capable of performing a wide range of treatments efficaciously and safely. Fulfilling this need in the marketplace is Aerolase, a global technology leader for laser skin health. The company’s products are a result of over two decades of research and development, and they form an integrated, portable solution for dermatological conditions and in-demand aesthetic procedures. As a result, these lasers substantially improve patient outcomes and experiences while helping physicians practice medicine profitably and reduce the overall cost of care within the dermatology space. “We have set a new benchmark by transforming the aesthetic laser medicine based on patented design innovations and the breakthrough of the Microsecond Technology. This is evident via our patented lasers that not only deliver high-standard treatment but also safety and comfort to patients with all skin types,” states Pavel Efremkin, the Chairman and CEO at Aerolase.

One of Aerolase’s flagship products is the Neo Elite Laser, which is a single leading device-based solution for a complete approach to addressing medical and aesthetic skin concerns. Skin health professionals can treat patients with any skin type, between any age, suffering from any skin condition, using a single handpiece. The system couples high-power with a short pulse duration allowing treatment without the use of aesthetics, skin cooling, and prevent discomfort and risk of adverse effects post-treatment. Another breakthrough in the field of anti-aging is Aerolase’s Era Elite laser.

We have set a new benchmark by transforming the aesthetic laser medicine based on patented design innovations and the breakthrough of the Microsecond Technology. This is evident via our patented lasers that not only deliver high-standard treatment but also safety and comfort to patients with all skin types

It is a groundbreaking device for epidermal renewal and prejuvenation. It opts for a custom-made approach to creating new, younger skin using high-fluence in a collimated beam via a gentle 650-microsecond pulse duration. Aerolase has also made a significant revelation in treating vascular lesions and redness using the V650 Laser. This eliminates the potential risks of traditional technologies and negates the pain and adverse effects of long-pulsed lasers. Its unique pulse parameters and wavelengths can safely treat a range of vascular lesions, including deep and superficial vessels, thick lesions and plaques, diffuse redness, and more.

What lies at the core of all of Aerolase’s products is the essence of being a contactless treatment. As most patients have always raved about the levels of hygiene and comfort involved with the 36 FDA indications for all skin types and tanned skin, the company thereby established the #NoTouchAerolase treatment. This has brought forth a new level of care and standard within the market. Furthermore, all its devices have a unique air-cooled laser technology that improves air quality by filtering the air inside the laser handpiece and exposing it to high optical energy while preventing skin contact for patients during treatment. Throughout the R&D process, Aerolase has paid special heed to the needs of patients with darker skin tones. The traditional laser light is often absorbed by the melanin in their epidermis, thus resulting in unsatisfactory treatment results and potential burns. To resolve this issue, Aerolase’s contactless treatment provides an optimal option to reach the target areas seamlessly and improve outcomes. In addition, the company’s solutions help fulfill the end goal of patients, which is seeing treatment results without being inflicted with pain or be affected by downtime.

Aerolase has been one of the pioneers of revolutionary laser treatment, as is evident from the company receiving a 100 percent rating on a consumer rating website RealSelf. In addition, a Cosmopolitan Magazine has recognized it as the best facial laser in its Holy Grail Beauty Awards. It has also been ranked as the number one aesthetic laser in the practitioner pool by Dermascope Aesthetic International Association for three years. Furthermore, its products are the only ones showcased in the Galderma Global Innovation Center. With such renowned recognitions and accolades under its belt, Aerolase is on its way to expand its outreach into global markets more extensively. It will continue to grow its marketing and sales in the U.S and Canada. It has recently updated the CE mark on its products to gain more users across the European market. Following this, it will concentrate on gaining users in the Asian and Latin American front as well. “We will be inventing newer products and expand into other medical verticals in a way that we either surpass the gold standards of existing technology or match up to those. Our clinical research capabilities allow us to move in this direction and extend our expertise and technology for accelerated wound healing of chronic wounds within hospitals, nursing homes, and long term care facilities,” concludes Efremkin.